No serious adverse events emerged from the data
As dengue quietly expands its reach through warming climates and busier flight paths, a team of Barcelona researchers has offered travel medicine a steadying answer: the TAK-003 vaccine, Europe's first approved dengue immunization, appears safe and well-tolerated among travelers who have never lived where the virus is endemic. A real-world study of over a thousand vaccinated individuals in Catalonia found no serious adverse events, only the familiar, fleeting discomforts that accompany most vaccines. In a moment when the boundaries between endemic and non-endemic worlds are dissolving, this evidence arrives as both reassurance and a quiet call to act.
- Dengue is no longer a distant tropical concern — climate change and global travel are carrying it into new latitudes, and travel clinics have been vaccinating without robust safety data for non-endemic populations.
- A study of 1,028 travelers across eight Catalan health centers administered 1,851 doses and tracked every reaction, filling a critical evidence gap that had left clinicians uncertain.
- No serious adverse events emerged; most side effects were mild and short-lived — injection-site pain, headache, fatigue — the ordinary toll of an immune system waking up.
- Women, dengue survivors, and those simultaneously vaccinated against yellow fever showed higher reaction rates, but elderly and immunocompromised travelers — historically understudied — showed no elevated risk.
- The findings now shift the central question in travel medicine from whether TAK-003 is safe to how swiftly it can become a standard fixture in pre-travel care worldwide.
Researchers at Barcelona's Institute for Global Health and Clinical Hospital have published findings in The Lancet Regional Health Europe that could meaningfully change how travel clinics approach dengue prevention. Their study tracked more than a thousand travelers vaccinated in Catalonia through 2024 with TAK-003, Europe's first approved dengue vaccine, and found no serious adverse events across nearly 1,900 administered doses.
The motivation was practical urgency. Dengue is spreading as warming temperatures extend the range of the mosquitoes that carry it, and international travel continues to grow — yet solid safety data for people from non-endemic regions had been scarce. Lead author Daniel Camprubí and his team built a pharmacovigilance network across eight travel health centers to capture what actually happens when real travelers get vaccinated before their trips.
More than half of participants reported some side effect, but nearly all were mild or moderate and resolved on their own within days — soreness, headache, fatigue, general malaise. Certain groups did experience more reactions: women reported more localized effects, people previously infected with dengue had more systemic responses, and those receiving the dengue and yellow fever vaccines simultaneously showed higher rates of fever. Crucially, however, older adults and immunocompromised individuals — populations often left out of clinical trials — showed no increased risk, giving clinicians a clearer picture for their most vulnerable patients.
The vaccine also proved compatible with other routine travel immunizations when given alongside non-flavivirus shots, supporting the practical need to vaccinate comprehensively in a single clinic visit. With these findings in hand, travel medicine now has the evidence base to offer dengue protection confidently, and the conversation can move from safety questions toward the logistics of making TAK-003 a standard part of pre-travel care.
Barcelona researchers have released findings that could reshape how travel clinics approach dengue vaccination. A study of over a thousand people vaccinated in Catalonia through 2024 shows that TAK-003, Europe's first approved dengue vaccine, carries a reassuring safety record for travelers coming from regions where the virus does not naturally circulate.
The research, published in The Lancet Regional Health Europe and conducted jointly by the Institute for Global Health and Barcelona's Clinical Hospital, examined what happened after 1,851 vaccine doses were administered. No serious adverse events emerged from the data. While more than half the vaccinated people reported some kind of side effect, nearly all were mild or moderate in nature and temporary—the kind of thing that resolves on its own within days. The most common complaints were soreness at the injection site, headaches, fatigue, and general malaise.
This matters because dengue is spreading. Climate change is expanding the geographic range where the mosquitoes that carry it can survive. International travel is increasing. Yet until now, solid safety data on this vaccine in non-endemic populations has been scarce. "We wanted to fill that gap," explains Daniel Camprubí, the study's lead author, describing how his team set up pharmacovigilance monitoring across eight travel health centers in Catalonia. The work was methodical and grounded in real-world conditions—exactly where travelers actually get vaccinated before their trips.
The analysis did identify certain groups at higher risk for adverse reactions. Women experienced more side effects than men, though theirs tended to be localized to the injection site. People who had previously been infected with dengue reported more reactions, as did those who received the dengue vaccine at the same time as yellow fever vaccination. In these latter two groups, systemic effects like fever were more common. But here is what did not happen: older adults and people with existing health conditions showed no elevated risk. This is significant because these populations have historically been understudied in vaccine trials, leaving clinicians uncertain about safety.
The vaccine also played well with other routine travel vaccinations. When TAK-003 was given alongside non-flavivirus vaccines—the standard shots travelers often need—no additional adverse events appeared. This practical finding supports what travel medicine doctors actually need: the ability to vaccinate comprehensively in a single visit without worrying about compounded side effects.
The implications are straightforward. Travel clinics can now offer dengue protection to their patients with confidence that the vaccine is well-tolerated and that serious complications are not a concern. The data suggests that while some groups may experience more noticeable reactions, these remain manageable and temporary. As dengue continues its slow geographic creep northward and as more people cross international borders, having a safe, effective vaccine option for non-endemic populations fills a genuine public health need. The question now shifts from whether the vaccine is safe to how quickly it can be integrated into standard pre-travel care.
Citações Notáveis
We wanted to fill that gap in knowledge about vaccine safety in non-endemic populations— Daniel Camprubí, lead author of the study
We observed no increase in adverse reactions in people over 60 or with existing health conditions, groups that previously had very little evidence— Cesc Bertran, study co-author
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this vaccine works in people who've never had dengue before?
Because most dengue vaccines were tested in endemic countries where people had prior exposure. We didn't know how the immune system would respond in someone encountering dengue for the first time.
And the women had more side effects—was that unexpected?
Not entirely. Women often mount stronger immune responses to vaccines generally. But the important part is that their reactions were local, not systemic, and temporary.
What about the people who'd already had dengue once?
They showed more systemic reactions—fevers, that kind of thing. That makes biological sense. Their immune system recognized the vaccine as related to something it had fought before, so it responded more vigorously.
Why does it matter that older people didn't have more problems?
Because we had almost no data on them before. Clinicians were hesitant. Now they know they can vaccinate a 65-year-old without special concern.
So this is really about filling in the blanks?
Exactly. The vaccine was approved, but we were operating with incomplete information about who it was actually safe for. This study lets travel clinics do their job with confidence.